New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
May 1, 2018 - The FDA announced the permanent discontinuation of AstraZeneca’s Bydureon (exenatide) single-dose tray (SDT) formulation.
Download PDF
Return to publications
